Ventoux Biosciences

11/24/2025

Ventoux Bio is proud to support the Hands of Change podcast. Special thanks to Professor Jarad Martin for joining the show and sharing more about his active research, his personal journey with the disease, the importance of multi-disciplinary care and much more.
The Hands of Change podcast is available on all major podcast platforms.
https://www.ventouxbio.com/jarad-martin-patient-to-researcher-dupuytrens-radiation-therapy/
Dupuytren Research Group - Dupuytren Foundation

Radiation oncologist and Dupuytren’s patient Professor Jarad Martin shares his unique dual perspective on care and research. In this Hands of Change Podcast conversation, he discusses radiation therapy, the DEPART study, and the importance of multi‑disciplinary, patient‑centered approaches.

11/11/2025

With gratitude to those who protect our freedom.

10/06/2025

We have the chance to advance novel, disease slowing treatment for Dupuytren's. It's up to us - the patient community - to make it happen. Find the link to call contribution options in the first comment below.

09/24/2025

We are very excited to share a significant milestone as we have received a U.S. patent for novel therapy in Dupuytren's and related immune-fibrotic diseases. Please read the full release via the link below.

https://www.ventouxbio.com/ventoux-biosciences-new-dupuytrens-disease-therapy-patent/

06/17/2025

We partnered for change

We're thrilled to have teamed up with Life Science Cares San Diego for their summer food drive! Together with our local friends and partners, Ventoux Biosciences proudly donated around 250lbs of food to the Community Resource Center in Encinitas. A heartfelt thank you to everyone who contributed to this important initiative. 🙏

Your support makes a difference!

05/28/2025

Excited to be named 2025 Pre-Clinical BioPharma Company of the Year by GHP.

More information:
https://www.ventouxbio.com/ventoux-biosciences-named-best-pre-clinical-stage-biopharma-company/

05/27/2025

✨ Together, we can unlock hope for those living with Dupuytren's disease. ✨
Every hand tells a story. For millions of us with Dupuytren's disease, our stories are shaped by courage, resilience, and the quest for solutions. At Ventoux Biosciences, we're on a mission to advance groundbreaking research—and YOU can play a part.
💡 Three ways to support:
1️⃣ Invest in innovation through equity crowdfunding opportunities.
2️⃣ Join us as an angel investor shaping the future of treatment.
3️⃣ Donate to accelerate critical research.
Visit our website https://www.ventouxbio.com/investors/ to learn more about how you can hold hands with us on this journey. Together, we can reshape the future for Dupuytren's.

05/16/2025

DD affects ~5% of U.S. Adults, RA impacts 0.5-1% of adults in developed countries. Despite the large market and significant unmet patient needs - no disease slowing pharmacologic treatments are available for Dupuytren's disease. We are working to change that.

05/16/2025

🙌 It’s time to take action for Dupuytren’s disease!

Over 6 million people in the U.S. and 25 million in Europe are impacted, but together, we can drive change. 🌟 At Ventoux Biosciences, we’re advancing innovative research with VEN-201, an immuno-modulator that disrupts thee pathologically cycle driving fibrosis.

💡 Here’s how you can help:

Want to invest? Check out our equity options (Reg-D or WeFunder).

Prefer to donate? Every dollar counts on GoFundMe.

🔗 Links in bio. Join the movement today and help transform lives! Please email IR@VentouxBio with any questions or to talk further. 💙

Transforming care for under-served immune-fibrotic dieases, lead progam in Dupuytren’s

05/13/2025

We are thrilled to be attending the International Dupuytren’s Symposia in Brussels. Ken Lipson, PhD, Chief Scientific Officer will be representing Ventoux Bio and is excited to meet fellow champions for change for Dupuytren’s and related diseases.

05/13/2025

We are thrilled to attend the 2025 Dupuytren's International Conference! Our CSO, Ken Lipson, PhD will be representing Ventoux Biosciences to connect with this wonderful community, clinicians, researchers, and innovators.



International Dupuytren Society British Dupuytren's Society Dupuytren Research Group - Dupuytren Foundation Kurt Harrington

05/13/2025

We are thrilled to attend the 2025 Dupuytren's International Symposium in Brussels. Our Chief Scientific Officer, Ken Lipson, PhD will be representing Ventoux Biosciences to connect with researchers, clinicians, and innovators. Wonderful to have this community coming together and excited for the outputs.

British Dupuytren's SocietyDupuytren Research Group - Dupuytren Foundation International Dupuytren Society Kurt Harrington